Jim Slattery
Overview
Explore the profile of Jim Slattery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Morales D, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X
Clin Drug Investig
. 2019 Feb;
39(2):215.
PMID: 30725313
The article Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study, written by Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan...
12.
Hedenmalm K, Slattery J, Skibicka-Stepien I, Kurz X, Morales D
Eur J Clin Pharmacol
. 2019 Jan;
75(5):707-716.
PMID: 30675632
Purpose: There is increasing concern with regard to fatal intoxications with prescription opioids and tramadol poisonings. This study aimed to characterise prescribing patterns for tramadol in primary care in France...
13.
Morales D, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X
Clin Drug Investig
. 2018 Nov;
39(2):205-213.
PMID: 30465300
Background And Objective: Tendon rupture can result from fluoroquinolone exposure. The objective of this study was to quantify relative and absolute risk and determine how risk is affected by timing...
14.
Pacurariu A, Plueschke K, McGettigan P, Morales D, Slattery J, Vogl D, et al.
BMJ Open
. 2018 Sep;
8(9):e023090.
PMID: 30185579
Objective: Electronic healthcare databases (EHDs) are useful tools for drug development and safety evaluation but their heterogeneity of structure, validity and access across Europe complicates the conduct of multidatabase studies....
15.
Morales D, Slattery J, Pinheiro L, Kurz X, Hedenmalm K
Clin Drug Investig
. 2018 Aug;
38(10):927-933.
PMID: 30143952
Background And Objectives: In the USA the benefit-risk profile of fluoroquinolones for treating patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections (uUTIs)...
16.
Slattery J, Morales D, Pinheiro L, Kurz X
Drug Saf
. 2018 May;
41(10):951-958.
PMID: 29785475
Introduction: Intrauterine devices are implantable contraceptives of which some brands steadily release levonorgestrel over an extended time period. Exposure to a levonorgestrel-releasing intrauterine device has been associated with depression and,...
17.
Postigo R, Brosch S, Slattery J, van Haren A, Dogne J, Kurz X, et al.
Drug Saf
. 2018 Mar;
41(7):665-675.
PMID: 29520645
The analysis of safety data from spontaneous reporting systems has a proven value for the detection and analysis of the risks of medicines following their placement on the market and...
18.
Morales D, Slattery J, Evans S, Kurz X
BMC Med
. 2018 Jan;
16(1):6.
PMID: 29332605
Background: Antidepressant exposure during pregnancy has been associated with an increased risk of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in several observational studies. We performed a...
19.
Pacurariu A, Hoeve C, Arlett P, Genov G, Slattery J, Sturkenboom M, et al.
Pharmacoepidemiol Drug Saf
. 2017 Dec;
27(2):168-173.
PMID: 29278866
Background: The amount of drug exposure, pre and post approval, is considered to be a direct determinant of knowledge about the safety of a drug. A larger pre-approval exposed population...
20.
Pinheiro L, Candore G, Zaccaria C, Slattery J, Arlett P
Pharmacoepidemiol Drug Saf
. 2017 Nov;
27(1):38-45.
PMID: 29143393
Purpose: The European Medicines Agency developed an algorithm to detect unexpected increases in frequency of reports, to enhance the ability to detect adverse events that manifest as increases in frequency,...